Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 7/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | HPGDS | O60760 | 4/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4470346 | 0.97 | GPR119 (0.37) | GPR119TRPV3PDE10AGABRA1MAPK1 | |
| SCHEMBL4482079 | 0.80 | MAPK1 (0.44) | GPR119TRPV3PDE10AMAPK1 | |
| SCHEMBL629954 | 0.72 | TRPV3 (0.42) | TRPV3PDE10AMAPK1IDO1 | |
| SCHEMBL5562740 | 0.72 | USP30 (0.39) | GABRA1MAPK1IDO1 | |
| SCHEMBL17316549 | 0.70 | CACNA1G (0.40) | GPR119IDO1 | |
| SCHEMBL3540420 | 0.69 | IDO1 (0.40) | TRPV3PDE10AMAPK1IDO1 | |
| SCHEMBL29209494 | 0.69 | GAA (0.51) | — | |
| SCHEMBL16660961 | 0.69 | TRPV3 (0.40) | TRPV3PDE10AMAPK1 | |
| SCHEMBL9269519 | 0.69 | ALDH1A1 (0.44) | GPR119TRPV3MAPK1 | |
| SCHEMBL9521091 | 0.69 | GABRA5 (0.36) | GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586594-B2 | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | ABBVIE INC. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2117526-B1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | ABBOTT LAB (US) | 2013-04-03 | — | — | EP | disclosed |
| US-20120238581-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | ABBVIE INC. | 2012-09-20 | — | — | US | disclosed |
| US-8202878-B2 | Type 2 diabetes, obesity, elevated plasma triglycerides, metabolic syndrome, non-alcoholic steatohepatitis, and non-alcoholic fatty liver disease;Trans [4-(4-{3-[2-(1-adamantyl)-2-hydroxyethoxy]-1H-pyrazol-5-yl}phenyl)cyclohexyl]acetic acid | ABBOTT LABORATORIES (US) | 2012-06-19 | — | — | US | disclosed |
| US-20080182861-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | ABBVIE INC. | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238581-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | DGAT1, DGAT2, LCAT | GPR119 168/4885TRPV3 3104/4885PDE10A 1074/4885 |
| US-20080182861-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | DGAT1, DGAT2, LCAT | GPR119 162/4885TRPV3 3125/4885PDE10A 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.